Literature DB >> 15478471

Psychotropic medication in pregnancy: ethical aspects and clinical management.

Sarah K Allison1.   

Abstract

This article explores the dilemma of whether women with mental illness should take potentially teratogenic psychotropic medications during pregnancy, from both the maternal and fetal perspectives. Ethical and social aspects of the dilemma are presented to assist perinatal and psychiatric practitioners to provide holistic and competent care to the mother/fetus dyad. Specific fetal risks involved with maternal psychotropic drug use are described and contrasted with fetal risks of an untreated, psychiatrically ill mother. Nursing and healthcare considerations for the care of this population are presented in general, and specific psychotropics are reviewed for their risk profile in pregnancy. The article concludes with a discussion of actions to reduce maternal and fetal risk for women who are mentally ill and are currently taking, or considering taking, a psychotropic medication.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15478471     DOI: 10.1097/00005237-200407000-00003

Source DB:  PubMed          Journal:  J Perinat Neonatal Nurs        ISSN: 0893-2190            Impact factor:   1.638


  2 in total

1.  Red blood cell folate levels in pregnant women with a history of mood disorders: a case series.

Authors:  Elyse Yaremco; Angela Inglis; Sheila M Innis; Catriona Hippman; Prescilla Carrion; Yvonne Lamers; William G Honer; Jehannine Austin
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2013-06-13

Review 2.  Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes.

Authors:  Danielle Coppola; Leo J Russo; Robert F Kwarta; Ruana Varughese; Juergen Schmider
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.